Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
NewLeaf Symbiotics
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Developer of micro-organisms that improve plant health, promote early growth, and increase crop yield

Founded in 2012
Founded in

Company type Private Public ()
Company type

Industry Group agriculture & food

Sector crop inputs

TRL Range 7-8
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters St Louis, MO St Louis, United States
Address
City
State
Zip
Country

Parent Companies

Website

Updated by at on 03/28/2025

Traction
  • 1 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
Partnerships
Save
Add Partnership
Date Partner Type
11/07/2023
American Vanguard American Vanguard
Building on an agreement announced in October 2022, American Vanguard unit AMVAC and NewLeaf will collaborate to distribute biologicals to markets including Argentina, Brazil, Ukraine, and China. The extended relationship will expand American Vanguard’s GreenSolutions biological portfolio internationally and facilitate NewLeaf’s objective of securing wider penetration for its proprietary PPFM tech
View source    
Confirmed by American Vanguard
Channel Partner
Delete
Investment Rounds
Save

IPO INFORMATION

Date

IPO status

IPO Type

Amount

Initial shares

Ticker symbol

Exchange listed

Prospectus URL

Prospectus

Source URL

Source

Description

Cancel Save
Add Investment
Date Investors Type Amount
12/19/2023 Gullspang Re:Food Gullspang Re:Food , Otter Capital Otter Capital , S2G Investments S2G Investments , Leaps By Bayer Leaps By Bayer (4)
Post-money valuation of
With this final Series D close, NewLeaf will accelerate its efforts with pink-pigmented facultative methylotroph (PPFM) technology and adjacent technologies in the areas of biostimulants and microbial inoculants, biocontrol, nitrogen use efficiency, and methane mitigation.
 Growth Equity $45,000,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font